Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranbaxy Laboratories Limited

http://www.ranbaxy.com/

Latest From Ranbaxy Laboratories Limited

Sun Signs $485m Settlement Deal To Close Out Ranbaxy Antitrust Case

India’s Sun Pharma is set to hand over almost half-a-billion dollars to resolve claims that its Ranbaxy unit schemed to delay the launch of generic versions of three popular prescription drugs. The firm has denied all allegations as part of the deal, which must be signed off by a US district court.

Legal Issues Deals

Strides CEO: US COMPETES Act Creates Quality Differentiator

The $1m-$10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan believes. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.

Manufacturing Policy

Strides CEO: US COMPETES Act Creates Quality Differentiator

The $1-10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan tells Scrip. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.

Policy Manufacturing

Sun Pharma’s Ranbaxy Fails In Bid To Dodge Antitrust Suit

A US lawsuit accusing Sun Pharma’s Ranbaxy of violating racketeering and antitrust laws, thereby maintaining artificially inflated prices for three blockbuster drugs, is now set to go to trial in January next year, after a US district court in Massachusetts denied all motions for summary judgment.

Legal Issues Generic Drugs
See All

Company Information

UsernamePublicRestriction

Register